VolitionRx Q2 revenue up 83% to $396K; H1 test sales exceed full-year 2023

VOLITIONRX LTD

2025-Q2 EPS reported -$0.19 vs consensus -$1.02 ▲ beat (+81.4%)

Q2 revenue $396K (+83% YoY); H1 revenue $567K (+55% YoY).
Operating expenses down 24% YoY in Q2; targeting $10M annualized cost reductions.
Cash $6.0M at June 30; closed $7M registered direct offering with up to $14.5M in milestone-linked warrants.
Sold over 60,000 Nu.Q Vet Cancer Tests in H1 2024 (vs 58,000 full-year 2023); now available in 17 countries.
Engaged PharmaVentures to advise on licensing deals for Nu.Q Cancer and Capture-PCR.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.